NIL	Refocusing
ORG	Medical Research
NIL	PRINCETON
NIL	–
REL	In
DIS	an
IST	ideal
CON	world
NIL	,
DEF	the
CON	amount
AND	of
CON	money
PRO	we
NOW	spend
REL	on
IST	medical
CON	research
SUB	to
EXS	prevent
DIS	or
CON	cure
DIS	a
CON	disease
FUT	would
EXS	be
IST	proportional
REL	to
HAS	its
CON	seriousness
AND	and
DEF	the
CON	number
AND	of
CON	people
AND	who
EXS	suffer
REL	from
PRO	it
NIL	.
REL	In
DEF	the
IST	real
CON	world
NIL	,
QUC	90
UOM	%
AND	of
DEF	the
CON	money
EPS	spent
REL	on
IST	medical
CON	research
NOW	is
EXS	focused
REL	on
CON	conditions
AND	that
NOW	are
IST	responsible
REL	for
INT	just
QUC	10
UOM	%
AND	of
DEF	the
CON	deaths
AND	and
CON	disability
EXS	caused
REL	by
CON	diseases
IST	globally
NIL	.
REL	In
ALT	other
CON	words
NIL	,
DEF	the
CON	diseases
SUB	that
EXS	cause
CON	nine-tenths
AND	of
QUE	what
DEF	the
ORG	World Health
ORG	Organization
NOW	refers
REL	to
AND	as
NIL	“
DEF	the
IST	global
CON	burden
AND	of
CON	disease
NIL	”
NOW	are
EXG	getting
XCL	only
CON	one-tenth
AND	of
DEF	the
CON	world
NOW	’s
IST	medical
CON	research
CON	effort
NIL	.
AND	As
DIS	a
CON	result
EQU	,
CON	millions
AND	of
CON	people
ENS	die
AND	every
CON	year
REL	from
CON	diseases
REL	for
UNK	which
AND	no
IST	new
CON	drugs
NOW	are
REL	in
DEF	the
CON	pipeline
NIL	,
AND	while
CON	drug
CON	companies
NOW	pour
CON	billions
REL	into
EXG	developing
CON	cures
REL	for
CON	erectile
CON	dysfunction
AND	and
CON	baldness
NIL	.
AND	But
EXS	blaming
CON	drug
CON	companies
NOW	is
INT	too
EXS	easy
DIS	a
CON	response
NIL	.
PRO	They
POS	can
NOT	not
EXS	justify
EXG	developing
IST	new
CON	drugs
SUB	unless
PRO	they
POS	can
EXS	expect
REL	to
CON	recoup
HAS	their
CON	costs
AND	through
CON	sales
NIL	.
IMP	If
PRO	they
CON	target
CON	diseases
SUB	that
EXS	affect
IST	affluent
CON	people
EQU	,
DIS	or
CON	people
EXS	living
REL	in
CON	countries
REL	with
IST	national
CON	health
CON	insurance
NIL	,
PRO	they
FUT	will
EXS	be
IST	able
SUB	to
CON	patent
AND	any
IST	new
CON	drugs
PRO	they
EXS	discover
NIL	.
REL	For
DEF	the
QUC	20
CON	years
AND	that
DEF	the
CON	patent
ENS	lasts
NIL	,
PRO	they
FUT	will
EXS	have
DIS	a
CON	monopoly
REL	on
DEF	the
CON	drug
AND	’s
CON	sale
AND	and
EXS	be
UNK	able
SUB	to
EXS	command
DIS	a
IST	high
CON	price
NIL	.
IMP	If
CON	drug
CON	companies
CON	target
CON	diseases
SUB	that
EXS	affect
IST	only
CON	people
AND	who
NOW	are
IST	unable
SUB	to
EXS	pay
IST	high
CON	prices
REL	for
CON	drugs
NIL	,
PRO	they
POS	can
NOT	not
EXS	expect
SUB	to
EXS	cover
HAS	their
CON	research
CON	costs
NIL	,
EXS	let
AND	alone
EXS	make
DIS	a
CON	profit
NIL	.
NOT	No
EXS	matter
QUE	how
QUV	much
HAS	their
ROL	directors
POS	may
EXS	want
SUB	to
EXS	focus
REL	on
DEF	the
CON	diseases
SUB	that
EXS	kill
DEF	the
TOP	most
CON	people
NIL	,
DEF	the
IST	current
CON	system
AND	of
IST	financial
CON	incentives
NOW	means
SUB	that
IMP	if
PRO	they
PST	did
IST	so
NIL	,
HAS	their
CON	shareholders
FUT	would
EXS	remove
PRO	them
NIL	,
DIS	or
HAS	their
CON	companies
FUT	would
IST	soon
EXS	be
IST	out
AND	of
CON	business
NIL	.
DST	That
FUT	would
EXS	help
NOT	no
CON	one
NIL	.
DEF	The
CON	problem
NOW	is
REL	with
DEF	the
CON	system
NIL	,
NOT	not
REL	with
DEF	the
CON	individuals
AND	who
EXS	make
HAS	their
CON	choices
AND	within
PRO	it
NIL	.
REL	At
DIS	a
CON	meeting
REL	in
GEO	Oslo
REL	in
MOY	August
NIL	,
ORG	Incentives
REL	for
ORG	Global
ORG	Health
EQU	,
DIS	a
IST	nonprofit
CON	organization
EXS	directed
REL	by
PER	Aidan
PER	Hollis
EQU	,
ROL	professor
AND	of
CON	economics
REL	at
DEF	the
ORG	University
AND	of
GEO	Calgary
NIL	,
COO	and
PER	Thomas
PER	Pogge
EQU	,
ROL	professor
AND	of
CON	philosophy
AND	and
IST	international
CON	affairs
REL	at
ORG	Yale
NIL	,
EPS	launched
DIS	a
IST	radical
IST	new
CON	proposal
SUB	to
EXS	change
DEF	the
CON	incentives
REL	under
UNK	which
CON	corporations
NOW	are
EXS	rewarded
REL	for
EXG	developing
IST	new
CON	medicines
NIL	.
PRO	They
NOW	suggest
SUB	that
CON	governments
EXS	contribute
REL	to
DIS	a
CON	Health
ORG	Impact
ORG	Fund
SUB	that
FUT	would
EXS	pay
REL	pharmaceutical
CON	companies
REL	in
CON	proportion
REL	to
DEF	the
CON	extent
REL	to
AND	which
HAS	their
CON	products
EXS	reduce
DEF	the
IST	global
CON	burden
AND	of
CON	disease
NIL	.
DEF	The
CON	fund
FUT	would
NOT	not
EXS	replace
EXG	existing
CON	patent
CON	laws
NIL	,
BUT	but
FUT	would
EXS	offer
DIS	an
CON	alternative
REL	to
PRO	them
NIL	.
ORG	Pharmaceutical
CON	companies
POS	could
EXS	continue
REL	to
CON	patent
COO	and
EXS	sell
HAS	their
CON	products
SUB	as
PRO	they
NOW	do
NOW	now
NIL	.
CON	Alternatively
NIL	,
PRO	they
POS	could
CON	register
DIS	a
IST	new
CON	drug
REL	with
DEF	the
IST	Heath Impact
ORG	Fund
NIL	,
AND	which
FUT	would
EXS	set
DIS	a
IST	low
CON	price
EXS	based
REL	on
DEF	the
CON	drug
AND	’s
CON	manufacturing
CON	cost
NIL	.
